Morepen Laboratories Limited — PPTs, 04-08-2026: Investor Presentation

Morepen Laboratories posted its highest-ever quarterly revenue of Rs. 575.31 Cr, up 34% YoY, signaling strong operational execution. Profit After Tax (PAT) surged 394% YoY to Rs. 56.35 Cr, with EBITDA growing 207% YoY to Rs. 87.72 Cr and margins hitting over 15%. This impressive performance reflects commercial validation of its "Morepen 2.0" strategy, shifting towards innovation-led manufacturing and long-duration CDMO projects.

A key highlight is the Rs. 58 Cr in commercial dispatches from a substantial Rs. 825 Cr CDMO mandate. The API business achieved 31% growth and is returning to healthy profitability, complemented by a 19% growth in Medical Devices, a scalable platform expanding into chronic care. Export revenue saw a remarkable 111% jump.

The company plans significant capacity augmentation, aiming to expand from 535 KL to 1200 KL by FY30 to support global CDMO opportunities. Management's outlook emphasizes continued commercial CDMO supplies, API profitability recovery, and driving long-term value through innovation, global partnerships, and sustainable operations, backed by a strong regulatory track record.